研究单位：[1]Sellas Life Sciences Group[2]Genfleet Therapeutics (Shanghai) Inc.[3]Sellas Life Sciences Group[4]O'Neal Comprehensive Cancer Center, University of Alabama,Birmingham,Alabama,United States,35233[5]Ochsner Clinic Foundation,New Orleans,Louisiana,United States,70121[6]Clinical Research Alliance, Inc.,Lake Success,New York,United States,11042[7]New York - Presbyterian Hospital,New York,New York,United States,10032[8]Bon Secours St. Francis Cancer Center,Greenville,South Carolina,United States,29607[9]MD Anderson,Houston,Texas,United States,77091[10]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China[11]Anhui Provincial Hospital,Hefei,Anhui,China[12]Affiliated Cancer Hospital of Chongqing University,Chongqing,Chongqing,China[13]Cancer prevention and treatment center of Sun Yat sen University,Guangzhou,Guangdong,China[14]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China[15]Affiliated Hospital of Hebei University,Baoding,Hebei,China[16]Henan Cancer Hospital,Zhengzhou,Henan,China,450000[17]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China[18]The First Affiliated Hospital Of Nanchang University,Nanchang,Jiangxi,China[19]Shengjing Hospital Affiliated to China Medical University,Shenyang,Liaoning,China[20]Linyi Cancer Hospital,Linyi,Shandong,China[21]Blood disease hospital, Chinese Academy of Medical Science,Tianjin,Tianjin,China,300000[22]The Second Affiliated hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310000
GFH009 is a potent and highly selective CDK9 inhibitor. To assess the safety, tolerability, and antitumor activity of single agent GFH009, this study consists of two dose escalation groups in patients with relapsed/refractory acute myeloid leukemia (Group 1) and in patients with relapsed/refractory lymphomas (Group 2). The safety, tolerability, and antitumor activity of GFH009 in combination with venetoclax and azacitidine in patients with relapsed/refractory acute myeloid leukemia (AML) who have relapsed on or are refractory to venetoclax-based regimens will also be assessed (Group 3).
